Semaglutide FDA approval covers Ozempic, Rybelsus, and Wegovy for diabetes, weight management, and heart risk. Learn what is approved and what is not.
Semaglutide is FDA-approved for type 2 diabetes and chronic weight management under the brand names Ozempic, Rybelsus, and Wegovy. The FDA has also approved certain semaglutide products for cardiovascular risk reduction in specific patient groups. Compounded semaglutide and research-grade semaglutide are not FDA-approved for human use.
What FDA Approval Means for Semaglutide
FDA approval means the agency reviewed clinical trial data for safety, effectiveness, and manufacturing quality. The FDA semaglutide review process is product-specific, meaning each brand must show safety and efficacy for its proposed use. Ozempic, Rybelsus, and Wegovy each have their own approved uses, doses, and labels.
A prescription from a licensed healthcare professional is required for all FDA-approved semaglutide products. The FDA does not approve dietary supplements, research peptides, or compounded drugs in the same way it approves brand-name medications.
FDA-Approved Semaglutide Products at a Glance
| Brand Name | Active Ingredient | FDA Approval Date | Approved Use | Route |
|---|---|---|---|---|
| Ozempic | semaglutide | December 5, 2017 | Type 2 diabetes; cardiovascular risk reduction in adults with type 2 diabetes and heart disease | Weekly injection |
| Rybelsus | semaglutide | September 20, 2019 | Type 2 diabetes | Daily oral tablet |
| Wegovy | semaglutide | June 4, 2021 | Chronic weight management; cardiovascular risk reduction in adults with obesity or overweight and heart disease | Weekly injection |
The table above shows that semaglutide is not a single approved product. Each brand has a distinct FDA-approved label. Using a product outside its approved indication is considered off-label use.
What the FDA Has Approved Semaglutide For
The FDA has approved semaglutide for three main purposes:
- Type 2 diabetes: Ozempic and Rybelsus help control blood sugar in adults with type 2 diabetes.
- Chronic weight management: Wegovy is approved for adults with obesity or overweight plus at least one weight-related condition, such as high blood pressure or high cholesterol.
- Cardiovascular risk reduction: Wegovy and Ozempic are approved to reduce the risk of major cardiovascular events in certain adults with heart disease.
Approval for weight management does not mean semaglutide is approved for cosmetic weight loss. The FDA indication specifically targets people with obesity or overweight and a related health condition.
What Semaglutide Is Not FDA-Approved For
Many people ask is semaglutide fda-approved for weight loss, and the answer depends on the product. Wegovy is approved for chronic weight management, but Ozempic and Rybelsus are not approved for weight loss. Using them for that purpose is off-label.
Compounded semaglutide is not FDA-approved. The FDA has warned that some compounded versions may use different forms of semaglutide, such as semaglutide sodium or semaglutide acetate, and may not have the same safety or effectiveness as approved products.
Research-grade semaglutide sold online is also not FDA-approved. These products are not intended for human consumption and may be unsafe.
Semaglutide FDA Approval Dates and Timeline
The semaglutide fda approval date for Ozempic was December 5, 2017, while Rybelsus followed on September 20, 2019, and Wegovy on June 4, 2021. Wegovy later received an expanded approval for cardiovascular risk reduction in March 2024.
Ozempic received its cardiovascular indication in January 2020. These dates matter because they show how the FDA's review has evolved as new clinical trial data became available.
How Semaglutide Compares to Other Peptides and Research Compounds
Semaglutide is a GLP-1 receptor agonist, not a research peptide. For comparison, is aod-9604 fda approved has a clear answer: AOD-9604 is not FDA-approved for human use.
A combination of cagrilintide and semaglutide is under investigation as CagriSema, but it is not FDA-approved.
In fitness and research circles, is cjc-1295/ipamorelin fda-approved is a common question, and the answer is no; this peptide combination is not FDA-approved for human use. Semaglutide's approved status is the exception, not the rule, among peptides.
Safety, Side Effects, and FDA Warnings
FDA-approved semaglutide products carry a boxed warning about thyroid C-cell tumors. Semaglutide is contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome.
Common side effects include nausea, vomiting, diarrhea, constipation, and abdominal pain. More serious risks include pancreatitis, gallbladder disease, kidney injury, and diabetic retinopathy complications.
Anyone considering semaglutide should talk with a healthcare professional. Do not use semaglutide without a prescription, and do not buy research-grade or compounded semaglutide from unverified sources.
How to Verify If a Semaglutide Product Is FDA-Approved
Check the FDA's Orange Book or the product's prescribing information. FDA-approved semaglutide products have a brand name, a New Drug Application (NDA) number, and a detailed label.
Compounded semaglutide does not have an FDA-approved label. If a product is sold as a "research chemical" or without a prescription, it is not FDA-approved for human use.
Bottom Line
Semaglutide is FDA-approved for type 2 diabetes, chronic weight management, and certain cardiovascular risk reduction. The approval is product-specific and does not cover compounded or research-grade semaglutide.
Patients should consult a healthcare professional and use only prescribed, FDA-approved semaglutide products.
Frequently Asked Questions
Is semaglutide FDA-approved?
Yes, semaglutide is FDA-approved under the brand names Ozempic, Rybelsus, and Wegovy. Each brand has specific approved uses, including type 2 diabetes, chronic weight management, and cardiovascular risk reduction. Compounded semaglutide is not FDA-approved.
What is the semaglutide FDA approval date?
Ozempic was approved on December 5, 2017. Rybelsus was approved on September 20, 2019. Wegovy was approved on June 4, 2021, and received an expanded cardiovascular indication in March 2024.
Is compounded semaglutide FDA-approved?
No, compounded semaglutide is not FDA-approved. The FDA has warned that compounded versions may use different forms of semaglutide and may not have the same safety, efficacy, or quality as approved products. Patients should use only prescribed, FDA-approved semaglutide.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.